Ulipristal acetate: new measures to minimise risk of rare but serious liver injury

June 1, 2018 – The European Medicines Agency (EMA) has recommended that several measures be put in place to minimise the risk of rare but serious liver injury with Ulipristal acetate. Certain women may start treatment with Ulipristal acetate once the new measures are implemented. The measures include: contraindication in women with known liver problems; liver tests before, during and after stopping treatment; a card for patients to inform them about the need for liver … (leggi tutto)